Hemostasis Screening Assays

  • George M. RodgersEmail author
  • Christopher M. Lehman


The cornerstone assays of coagulation testing are the prothrombin time (PT) and partial thromboplastin time (PTT). When combined with results of the platelet count obtained from the complete blood count (CBC), differential diagnoses can be generated to assist in the evaluation of patients with bleeding disorders. This chapter will summarize methodologies for the PT and PTT assays, as well as other clinically useful tests that many hospital laboratories provide. An approach to diagnosing bleeding disorders using results of the PT and PTT assays (and the platelet count) will also be presented. Lastly, limitations of these assays will be discussed in the context of evaluating patients for bleeding. All assays discussed in this chapter have FDA approval.


Prothrombin Time Partial Thromboplastin Time Bleeding Disorder Fibrinogen Concentration Platelet Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rodgers GM. Case studies in hemostasis. Chicago: ASCP Press; 2000. p. 161.Google Scholar
  2. 2.
    Rodgers GM. Thrombocytopenia. In: Kjeldsberg CR, editor. Practical diagnosis of hematologic disorders. 4th ed. Chicago: ASCP Press; 2006.Google Scholar
  3. 3.
    Rodgers GM. The diagnostic approach to the bleeding disorders. In: Greer JP, Foerster J, Lukens JN, editors. Wintrobe’s clinical hematology. 11th ed. Baltimore: Lippincott, Williams & Wilkins; 2004. p. 1511–28.Google Scholar
  4. 4.
    Hougie C. Partial thromboplastin time and activated partial thromboplastin time tests: one stage prothrombin time. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, editors. Hematology. 4th ed. New York: McGraw-Hill; 1990. p. 1766–70.Google Scholar
  5. 5.
    Lowe GDO, Rumley A, Mackie IJ. Plasma fibrinogen. Ann Clin Biochem. 2004;41:430–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Mackie IJ, Kitchen S, Machin SJ, The Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology, et al. Guidelines on fibrinogen assays. Br J Haematol. 2003;121:396–404.PubMedCrossRefGoogle Scholar
  7. 7.
    Lehman CM, Wilson LW, Rodgers GM. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric D-Dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004;122:178–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Stein PD, Hull RD, Patel KC, et al. D-Dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Intern Med. 2004;140:589–602.PubMedCrossRefGoogle Scholar
  9. 9.
    Lehman CM, Blaylock RC, Alexander DP, et al. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem. 2001;47:1204–11.PubMedGoogle Scholar
  10. 10.
    Rodgers GM. Common clinical bleeding disorders. In: Boldt DH, editor. Update on hemostasis. New York: Churchill Livingstone; 1990. p. 75–120.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of HematologyUniversity of Utah Health Sciences CenterSalt Lake CityUSA
  2. 2.Coagulation LaboratoryARUP LaboratoriesSalt Lake CityUSA
  3. 3.Department of PathologyUniversity of Utah Health Sciences CenterSalt Lake CityUSA
  4. 4.Hospital Clinical LaboratoriesARUP LaboratoriesSalt Lake CityUSA

Personalised recommendations